EU Commission does not accept EMA rejection of Duchenne muscular dystrophy drug Translarna
Unusually, the European Commission has not followed a recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to reject a renewal of the conditional marketing authorization for Translarna (ataluren) from PTC Therapeutics, the latter writes in a statement.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
CHMP recommends nine drugs in September
For subscribers